Eliquis approved for DVT and PE

Eliquis (apixaban) is now licensed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults.

Eilquis (apixaban) can be used instead of combination warfarin and a low molecular weight heparin for the treatment of pulmonary embolism (pictured). | SCIENCE PHOTO LIBRARY
Eilquis (apixaban) can be used instead of combination warfarin and a low molecular weight heparin for the treatment of pulmonary embolism (pictured). | SCIENCE PHOTO LIBRARY

Patients being treated for acute DVT or PE should receive apixaban 10mg twice for the first 7 days, followed by 5mg twice daily.

The recommended dose for the prevention of recurrent DVT or PE in adults is 2.5mg twice daily, following 6 months of apixaban at the treatment dose or another conventional anticoagulant.

Apixaban is not recommended for haemodynamically unstable PE or patients who require thrombolysis or pulmonary embolectomy, and for patients with active cancer.

Mechanism of action

Apixaban directly inhibits factor Xa, thereby preventing thrombin formation and clot development. Like rivaroxaban and dabigatran, it does not require routine anticoagulation monitoring.

Clinical studies

In the double-blind 12-month AMPLIFY trial, apixaban was non-inferior to enoxaparin/warfarin for the prevention of recurrent VTE/VTE-related death, and was associated with a lower risk of major bleeding (RR 0.31, 95% CI 0.17–0.55, p<0.0001).

In the double-blind, placebo-controlled 12-month extension trial AMPLIFY-EXT (n=2486), patients treated with apixaban had a significantly lower rate of recurrent VTE/all-cause death than those given placebo (1.7% vs 8.8%, p<0.001) and rates of major bleeding did not differ significantly between the groups.

Other indications

This latest indication update means that the licensed indications of Eliquis are now the same as those of Xarelto (rivaroxaban) and Pradaxa (dabigatran).

View Eliquis drug record

Further information: BMS

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more